SARM-2f

Compound 2f (SARM) is a cutting-edge drug developed by Takeda Pharmaceutical, initially targeting the treatment of prostate cancer. As a selective androgen receptor modulator (SARM), it exhibits potent yet tissue-specific androgenic effects,. This unique characteristic allows it to deliver anabolic benefits to muscles and the central nervous system while minimizing impact on the prostate gland.

Animal studies have further demonstrated its ability to induce sexual behavior, highlighting its potential in various therapeutic applications. With its promising pharmacological profile, Compound 2f (SARM) represents a significant advancement in the field of androgen receptor-targeted therapies, offering a novel approach to treating conditions that require selective androgenic stimulation.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Compound_2f_(SARM)